Russ Reiss

Russ Reiss is an accomplished professional in the life sciences field, currently serving as Chief Operating Officer at StrongHolt Therapeutics since 2022, where the focus is on AAV-based gene therapy for Duchenne muscular dystrophy. Reiss also holds advisory roles at GlycoMira Therapeutics and Xenter, providing expertise in therapeutics for mucosal diseases and innovative medical devices, respectively. As Chief Operating Officer and Board Member at SymbioCellTech, Reiss has contributed to developing stem cell-enabled technology for diabetes management. Furthermore, experience as a cardiothoracic surgeon is highlighted through positions at Parkview Medical Center, Timpanogos Regional Hospital, and UCHealth. Reiss has a robust educational background with MD and PhD studies, having attended multiple prestigious institutions including Drexel University and the University of Utah.